#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Use of rapid Model for End-Stage Liver Disease (MELD) increases for liver transplant registrant prioritization after MELD-Na and Share 35, an evaluation using data from the United Network for Organ Sharing


Autoři: Guy N. Brock aff001;  Kenneth Washburn aff002;  Michael R. Marvin aff004
Působiště autorů: Department of Biomedical Informatics and Center for Biostatistics, College of Medicine, The Ohio State University, Columbus, OH, United States of America aff001;  Department of Surgery, Division of Transplantation Surgery, Wexner Medical Center, The Ohio State University, Columbus, OH, United States of America aff002;  Center for Surgical Health Assessment, Research and Policy (SHARP), Wexner Medical Center, The Ohio State University, Columbus, OH, United States of America aff003;  Department of Transplantation and Liver Surgery, Geisinger Medical Center, Danville, PA, United States of America aff004
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0223053

Souhrn

The Model for End-Stage Liver Disease (MELD) score has been successfully used to prioritize patients on the United States liver transplant waiting list since its adoption in 2002. The United Network for Organ Sharing (UNOS)/Organ Procurement Transplantation Network (OPTN) allocation policy has evolved over the years, and notable recent changes include Share 35, inclusion of serum sodium in the MELD score, and a ‘delay and cap’ policy for hepatocellular carcinoma (HCC) patients. We explored the potential of a registrant’s change in 30-day MELD scores (ΔMELD30) to improve allocation both before and after these policy changes. Current MELD and ΔMELD30 were evaluated using cause-specific hazards models for waitlist dropout based on US liver transplant registrants added to the waitlist between 06/30/2003 and 6/30/2013. Two composite scores were constructed and then evaluated on UNOS data spanning the current policy era (01/02/2016 to 09/07/2018). Predictive accuracy was evaluated using the C-index for model discrimination and by comparing observed and predicted waitlist dropout probabilities for model calibration. After the change to MELD-Na, increased dropout associated with ΔMELD30 jumps is no longer evident at MELD scores below 30. However, the adoption of Share 35 has potentially resulted in discrepancies in waitlist dropout for patients with sharp MELD increases at higher MELD scores. Use of the ΔMELD30 to add additional points or serve as a potential tiebreaker for patients with rapid deterioration may extend the benefit of Share 35 to better include those in most critical need.

Klíčová slova:

Alcoholics – Cirrhosis – Coronary heart disease – Hepatocellular carcinoma – Liver diseases – Liver transplantation – Primary biliary cirrhosis


Zdroje

1. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70. doi: 10.1053/jhep.2001.22172 11172350

2. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R. Results of the first year of the new liver allocation plan. Liver Transpl. 2004;10(1):7–15. doi: 10.1002/lt.20024 14755772

3. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. Journal of hepatology. 2004;40(6):897–903. doi: 10.1016/j.jhep.2004.02.010 15158328

4. Bernardi M, Gitto S, Biselli M. The MELD score in patients awaiting liver transplant: strengths and weaknesses. Journal of hepatology. 2011;54(6):1297–306. doi: 10.1016/j.jhep.2010.11.008 21145851

5. Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005;41(1):32–9. doi: 10.1002/hep.20517 15690479

6. Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. The New England journal of medicine. 2008;359(10):1018–26. doi: 10.1056/NEJMoa0801209 18768945

7. Luca A, Angermayr B, Bertolini G, Koenig F, Vizzini G, Ploner M, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl. 2007;13(8):1174–80. doi: 10.1002/lt.21197 17663415

8. Sharma P, Schaubel DE, Sima CS, Merion RM, Lok AS. Re-weighting the model for end-stage liver disease score components. Gastroenterology. 2008;135(5):1575–81. doi: 10.1053/j.gastro.2008.08.004 18835388

9. Merion RM, Wolfe RA, Dykstra DM, Leichtman AB, Gillespie B, Held PJ. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl. 2003;9(1):12–8. doi: 10.1053/jlts.2003.50009 12514767

10. Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Lee PC, et al. Evaluation of the increase in model for end-stage liver disease (DeltaMELD) score over time as a prognostic predictor in patients with advanced cirrhosis: risk factor analysis and comparison with initial MELD and Child-Turcotte-Pugh score. Journal of hepatology. 2005;42(6):826–32. doi: 10.1016/j.jhep.2005.01.019 15885353

11. Gyori GP, Silberhumer GR, Zehetmayer S, Kern B, Hetz H, Soliman T, et al. Dynamic changes in MELD score not only predict survival on the waiting list but also overall survival after liver transplantation. Transplant international: official journal of the European Society for Organ Transplantation. 2012;25(9):935–40.

12. Northup PG, Berg CL. Preoperative delta-MELD score does not independently predict mortality after liver transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2004;4(10):1643–9.

13. Bambha K, Kim WR, Kremers WK, Therneau TM, Kamath PS, Wiesner R, et al. Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2004;4(11):1798–804.

14. D'Amico G. Developing concepts on MELD: delta and cutoffs. Journal of hepatology. 2005;42(6):790–2. doi: 10.1016/j.jhep.2005.03.009 15885348

15. Massie AB, Luo X, Alejo JL, Poon AK, Cameron AM, Segev DL. Higher Mortality in registrants with sudden model for end-stage liver disease increase: Disadvantaged by the current allocation policy. Liver Transpl. 2015;21(5):683–9. doi: 10.1002/lt.24102 25762287

16. Kalra A, Wedd JP, Biggins SW. Changing prioritization for transplantation: MELD-Na, hepatocellular carcinoma exceptions, and more. Curr Opin Organ Transplant. 2016;21(2):120–6. doi: 10.1097/MOT.0000000000000281 26825358

17. Kwong AJ, Goel A, Mannalithara A, Kim WR. Improved posttransplant mortality after share 35 for liver transplantation. Hepatology. 2018;67(1):273–81. doi: 10.1002/hep.29301 28586179

18. Goldberg DS, Levine M, Karp S, Gilroy R, Abt PL. Share 35 changes in center-level liver acceptance practices. Liver Transpl. 2017;23(5):604–13. doi: 10.1002/lt.24749 28240804

19. Berumen J, Misel M, Vodkin I, Halldorson JB, Mekeel KL, Hemming A. The effects of Share 35 on the cost of liver transplantation. Clin Transplant. 2017;31(5).

20. Policy and system changes effective January 11, 2016, adding serum sodium to MELD calculation—UNOS [07/29/2019]. Available from: https://unos.org/news/policy-and-system-changes-effective-january-11-2016-adding-serum-sodium-to-meld-calculation/.

21. Sharma P, Schaubel DE, Goodrich NP, Merion RM. Serum sodium and survival benefit of liver transplantation. Liver Transpl. 2015;21(3):308–13. doi: 10.1002/lt.24063 25504743

22. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130(6):1652–60. doi: 10.1053/j.gastro.2006.02.010 16697729

23. Revised liver policy regarding HCC exception scores. In: Network UNfOSOPaT, editor.

24. Wedd JP, Nordstrom E, Nydam T, Durham J, Zimmerman M, Johnson T, et al. Hepatocellular carcinoma in patients listed for liver transplantation: Current and future allocation policy and management strategies for the individual patient. Liver Transpl. 2015;21(12):1543–52. doi: 10.1002/lt.24356 26457885

25. Ishaque T, Massie AB, Bowring MG, Haugen CE, Ruck JM, Halpern SE, et al. Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2019;19(2):564–72.

26. Marvin MR, Ferguson N, Cannon RM, Jones C, Brock GN. MELD: An alternative MELD score for patients with hepatocellular carcinoma. Liver Transpl. 2015.

27. Harrell FE Jr., Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. Jama. 1982;247(18):2543–6. 7069920

28. R: A Language and Environment for Statistical Computing [Internet]. R Foundation for Statistical Computing. 2019. Available from: http://www.R-project.org.

29. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer; 2000.


Článek vyšel v časopise

PLOS One


2019 Číslo 10
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

KOST
Koncepce osteologické péče pro gynekology a praktické lékaře
nový kurz
Autoři: MUDr. František Šenk

Sekvenční léčba schizofrenie
Autoři: MUDr. Jana Hořínková

Hypertenze a hypercholesterolémie – synergický efekt léčby
Autoři: prof. MUDr. Hana Rosolová, DrSc.

Svět praktické medicíny 5/2023 (znalostní test z časopisu)

Imunopatologie? … a co my s tím???
Autoři: doc. MUDr. Helena Lahoda Brodská, Ph.D.

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#